The risk of radiation-induced neurocognitive impairment and the impact of sparing the hippocampus during pediatric proton cranial irradiation

• Published in: Acta oncologica Vol. 62; no. 2; p. 134
• Main Authors: Gram, Daniel, Brodin, N Patrik, Björk-Eriksson, Thomas, Nysom, Karsten, Munck Af Rosenschöld, Per
• Format: Journal Article
• Language: English
• Published: England 01-02-2023
• Subjects: Child; Cranial Irradiation - adverse effects; Cranial Irradiation - methods; Hippocampus - radiation effects; Humans; Organs at Risk - radiation effects; Proton Therapy - adverse effects; Proton Therapy - methods; Protons; Radiotherapy Dosage; Radiotherapy Planning, Computer-Assisted - methods; Radiotherapy, Intensity-Modulated - adverse effects; Radiotherapy, Intensity-Modulated - methods; craniospinal irradiation; pediatric hippocampus; Neurocognitive impairment; tumor control probability; hippocampal avoidance; normal tissue complication probability
• ISSN: 1651-226X
• DOI: 10.1080/0284186X.2023.2176253

Hippocampus is a central component for neurocognitive function and memory. We investigated the predicted risk of neurocognitive impairment of craniospinal irradiation (CSI) and the deliverability and effects of hippocampal sparing. The risk estimates were derived from published NTCP models. Specifically, we leveraged the estimated benefit of reduced neurocognitive impairment with the risk of reduced tumor control.
For this dose planning study, a total of 504 hippocampal sparing intensity modulated proton therapy (HS-IMPT) plans were generated for 24 pediatric patients whom had previously received CSI. Plans were evaluated with respect to target coverage and homogeneity index to target volumes, maximum and mean dose to OARs. Paired t-tests were used to compare hippocampal mean doses and normal tissue complication probability estimates.
The median mean dose to the hippocampus could be reduced from 31.3 Gy
to 7.3 Gy
(
 < .001), though 20% of these plans were not considered clinically acceptable as they failed one or more acceptance criterion. Reducing the median mean hippocampus dose to 10.6 Gy
was possible with all plans considered as clinically acceptable treatment plans. By sparing the hippocampus to the lowest dose level, the risk estimation of neurocognitive impairment could be reduced from 89.6%, 62.1% and 51.1% to 41.0% (
 < .001), 20.1% (
 < .001) and 29.9% (
 < .001) for task efficiency, organization and memory, respectively. Estimated tumor control probability was not adversely affected by HS-IMPT, ranging from 78.5 to 80.5% for all plans.
We present estimates of potential clinical benefit in terms of neurocognitive impairment and demonstrate the possibility of considerably reducing neurocognitive adverse effects, minimally compromising target coverage locally using HS-IMPT.